08:01 AM EDT, 07/11/2025 (MT Newswires) -- GSK (GSK), Pfizer ( PFE ) , and Boehringer Ingelheim prevailed as the Delaware Supreme Court reversed a lower court's decision to admit expert testimony in nearly 75,000 Zantac-related cancer lawsuits, the court said Thursday.

The justices ruled that the plaintiffs' experts failed to reliably link ranitidine, the active ingredient in Zantac, to cancer risk, citing flawed use of unrelated NDMA studies.

The court also said the trial judge misapplied Delaware Rule of Evidence 702 by treating reliability challenges as jury matters without proper vetting.

It also clarified that general causation must address the specific drug, not just its potential byproducts, unless backed by valid science, the ruling stated.